Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 9329fd28-b848-4013-92e0-a68270328336

Revlimid

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2023-03-24
Captured
2026-09-09T23:37:54.830918+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID ® treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment [see Warnings and Precautions ( 5.1 ), and Medication Guide ( 17 )]. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the Lenalidomide REMS program ( 5.2 ). Information about the Lenalidomide REMS program is available at www.lenalidomiderems.com or by calling the REMS Call Center at 1-888-423-5436. Hematologic Toxicity (Neutropenia and Thrombocytopenia) REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q myelodysplastic syndromes had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q myelodysplastic syndromes should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors [see Dosage and Administration ( 2.2 )] . Venous and Arterial Thromboembolism REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients about signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the patient’s underlying risks [see Warnings and Precautions ( 5.4 )]. WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO-FETAL TOXICITY • Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study similar to birth defects caused by thalidomide in humans. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. • Pregnancy must be excluded before start of treatment. Prevent pregnancy during treatment by the use of two reliable methods of contraception ( 5.1 ). REVLIMID is available only through a restricted distribution program, called the Lenalidomide REMS program ( 5.2 , 17 ). HEMATOLOGIC TOXICITY. REVLIMID can cause significant neutropenia and thrombocytopenia ( 5.3 ). VENOUS AND ARTERIAL THROMBOEMBOLISM Significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma receiving REVLIMID with dexamethasone. Anti-thrombotic prophylaxis is recommended ( 5.4 ).

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of Use REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) ] .
Full extracted label fields
application numbers
  1. NDA021880
boxed warning exact
  1. WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID ® treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment [see Warnings and Precautions ( 5.1 ), and Medication Guide ( 17 )]. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the Lenalidomide REMS program ( 5.2 ). Information about the Lenalidomide REMS program is available at www.lenalidomiderems.com or by calling the REMS Call Center at 1-888-423-5436. Hematologic Toxicity (Neutropenia and Thrombocytopenia) REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q myelodysplastic syndromes had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q myelodysplastic syndromes should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors [see Dosage and Administration ( 2.2 )] . Venous and Arterial Thromboembolism REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients about signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the patient’s underlying risks [see Warnings and Precautions ( 5.4 )]. WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO-FETAL TOXICITY • Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study similar to birth defects caused by thalidomide in humans. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. • Pregnancy must be excluded before start of treatment. Prevent pregnancy during treatment by the use of two reliable methods of contraception ( 5.1 ). REVLIMID is available only through a restricted distribution program, called the Lenalidomide REMS program ( 5.2 , 17 ). HEMATOLOGIC TOXICITY. REVLIMID can cause significant neutropenia and thrombocytopenia ( 5.3 ). VENOUS AND ARTERIAL THROMBOEMBOLISM Significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma receiving REVLIMID with dexamethasone. Anti-thrombotic prophylaxis is recommended ( 5.4 ).
brand names
  1. Revlimid
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be
generic names
  1. LENALIDOMIDE
id
9329fd28-b848-4013-92e0-a68270328336
indications and usage exact
  1. 1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of Use REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) ] .
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Celgene Corporation
    matched search terms
    1. lymphoma
    2. leukemia
    3. myeloma
    4. myelodysplastic
    package ndcs
    1. 59572-402-28
    2. 59572-402-00
    3. 59572-405-28
    4. 59572-405-00
    5. 59572-410-28
    6. 59572-410-00
    7. 59572-415-21
    8. 59572-415-00
    9. 59572-420-21
    10. 59572-420-00
    11. 59572-425-21
    12. 59572-425-00
    product ndcs
    1. 59572-402
    2. 59572-405
    3. 59572-410
    4. 59572-415
    5. 59572-420
    6. 59572-425
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
    1. Warnings and Precautions ( 5.1 , 5.2 ) 8/2021 Warnings and Precautions ( 5.1 , 5.11 ) 5/2022
    record type
    complete_spl_indications_section_candidate
    routes
    1. ORAL
    rxcuis
    1. 602910
    2. 602912
    3. 616114
    4. 616116
    5. 643712
    6. 643714
    7. 643720
    8. 643722
    9. 1242231
    10. 1242233
    11. 1428947
    12. 1429367
    source batch
    file
    /private/tmp/cancer-full-research/indications/raw/labels-00500.json
    meta
    disclaimer
    Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
    last updated
    2026-09-09
    results
    limit
    100
    skip
    500
    total
    830
    sha256
    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
    url
    https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=500&sort=id%3Aasc
    source url
    https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
    spl effective date
    2023-03-24
    spl effective time
    20230324
    spl set id
    5fa97bf5-28a2-48f1-8955-f56012d296be
    spl version
    41
    substance names
    1. LENALIDOMIDE
    uniis
    1. F0P408N6V4
    verification flags
    1. oncology_keyword_candidate_not_clinically_classified
    2. spl_text_not_verified_identical_to_latest_approved_label
    3. individual_indications_not_split_or_reconciled
    4. fda_label_posted_after_spl_effective_date_requires_version_review
    Drugs@FDA application source records
    1. application number
      NDA021880
      payload
      all indexed label documents
      1. Appl No
        021880
        Application Docs Date
        2010-08-10 00:00:00
        Application Docs ID
        16509
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        13
        Submission Type
        SUPPL
      2. Appl No
        021880
        Application Docs Date
        2009-02-24 00:00:00
        Application Docs ID
        16510
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        17
        Submission Type
        SUPPL
      3. Appl No
        021880
        Application Docs Date
        2010-10-19 00:00:00
        Application Docs ID
        16511
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        18
        Submission Type
        SUPPL
      4. Appl No
        021880
        Application Docs Date
        2011-12-23 00:00:00
        Application Docs ID
        16512
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        23
        Submission Type
        SUPPL
      5. Appl No
        021880
        Application Docs Date
        2013-02-12 00:00:00
        Application Docs ID
        16513
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        29
        Submission Type
        SUPPL
      6. Appl No
        021880
        Application Docs Date
        2014-09-19 00:00:00
        Application Docs ID
        16514
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        39
        Submission Type
        SUPPL
      7. Appl No
        021880
        Application Docs Date
        2015-02-24 00:00:00
        Application Docs ID
        16515
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        41
        Submission Type
        SUPPL
      8. Appl No
        021880
        Application Docs Date
        2005-12-28 00:00:00
        Application Docs ID
        37805
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        1
        Submission Type
        ORIG
      9. Appl No
        021880
        Application Docs Date
        2006-07-03 00:00:00
        Application Docs ID
        37806
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        1
        Submission Type
        SUPPL
      10. Appl No
        021880
        Application Docs Date
        2009-02-24 00:00:00
        Application Docs ID
        37807
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        6
        Submission Type
        SUPPL
      11. Appl No
        021880
        Application Docs Date
        2009-02-24 00:00:00
        Application Docs ID
        37808
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        16
        Submission Type
        SUPPL
      12. Appl No
        021880
        Application Docs Date
        2012-03-12 00:00:00
        Application Docs ID
        37809
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        28
        Submission Type
        SUPPL
      all submission records
      1. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        70
        Submission Status
        AP
        Submission Status Date
        2026-07-22 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      2. Appl No
        021880
        Review Priority
        N/A
        Submission Class Code ID
        21
        Submission No
        69
        Submission Status
        AP
        Submission Status Date
        2026-04-27 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      3. Appl No
        021880
        Review Priority
        N/A
        Submission Class Code ID
        21
        Submission No
        67
        Submission Status
        AP
        Submission Status Date
        2023-03-24 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      4. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        65
        Submission Status
        AP
        Submission Status Date
        2022-05-24 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      5. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        64
        Submission Status
        AP
        Submission Status Date
        2021-08-31 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      6. Appl No
        021880
        Review Priority
        N/A
        Submission Class Code ID
        21
        Submission No
        63
        Submission Status
        AP
        Submission Status Date
        2021-08-05 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      7. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        60
        Submission Status
        AP
        Submission Status Date
        2019-10-30 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      8. Appl No
        021880
        Review Priority
        PRIORITY
        Submission Class Code ID
        2
        Submission No
        57
        Submission Status
        AP
        Submission Status Date
        2019-05-28 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      9. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        56
        Submission Status
        AP
        Submission Status Date
        2019-01-22 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      10. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        55
        Submission Status
        AP
        Submission Status Date
        2017-12-29 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      11. Appl No
        021880
        Review Priority
        N/A
        Submission Class Code ID
        21
        Submission No
        54
        Submission Status
        AP
        Submission Status Date
        2020-09-24 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      12. Appl No
        021880
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        53
        Submission Status
        AP
        Submission Status Date
        2017-11-30 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      application number
      NDA021880
      approval interpretation
      Application linkage and approved submission are not indication-level current approval verification
      current indication status
      not_reconciled
      has approved submission record
      true
      latest approved submission date
      2026-07-22
      latest label selection rule
      max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
      latest posted label documents
      1. Appl No
        021880
        Application Docs Date
        2026-07-24 00:00:00
        Application Docs ID
        86681
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        70
        Submission Type
        SUPPL
      official application record
      Appl No
      021880
      Appl Public Notes
      Appl Type
      NDA
      Sponsor Name
      BRISTOL MYERS SQUIBB
      openfda application present
      true
      products
      1. Active Ingredient
        LENALIDOMIDE
        Appl No
        021880
        Drug Name
        REVLIMID
        Form
        CAPSULE;ORAL
        Product No
        001
        Reference Drug
        1
        Reference Standard
        0
        Strength
        5MG
        marketing status
        1. Prescription
      2. Active Ingredient
        LENALIDOMIDE
        Appl No
        021880
        Drug Name
        REVLIMID
        Form
        CAPSULE;ORAL
        Product No
        002
        Reference Drug
        1
        Reference Standard
        0
        Strength
        10MG
        marketing status
        1. Prescription
      3. Active Ingredient
        LENALIDOMIDE
        Appl No
        021880
        Drug Name
        REVLIMID
        Form
        CAPSULE;ORAL
        Product No
        003
        Reference Drug
        1
        Reference Standard
        0
        Strength
        15MG
        marketing status
        1. Prescription
      4. Active Ingredient
        LENALIDOMIDE
        Appl No
        021880
        Drug Name
        REVLIMID
        Form
        CAPSULE;ORAL
        Product No
        004
        Reference Drug
        1
        Reference Standard
        1
        Strength
        25MG
        marketing status
        1. Prescription
      5. Active Ingredient
        LENALIDOMIDE
        Appl No
        021880
        Drug Name
        REVLIMID
        Form
        CAPSULE;ORAL
        Product No
        005
        Reference Drug
        1
        Reference Standard
        0
        Strength
        2.5MG
        marketing status
        1. Prescription
      6. Active Ingredient
        LENALIDOMIDE
        Appl No
        021880
        Drug Name
        REVLIMID
        Form
        CAPSULE;ORAL
        Product No
        006
        Reference Drug
        1
        Reference Standard
        0
        Strength
        20MG
        marketing status
        1. Prescription

    Source passages and status connections

    Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

    Passage 1 · positive indication candidate
    application numbers
    1. NDA021880
    brand names
    1. Revlimid
    classification reasons
    1. explicit_positive_indication_predicate
    2. no_tumor_directed_keyword_in_positive_statement
    clinical review status
    pending
    content role
    positive_indication_candidate
    context span
    end
    310
    end exclusive
    true
    exact text
    1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anem
    label id
    9329fd28-b848-4013-92e0-a68270328336
    offset unit
    unicode_code_points
    source array index
    0
    source field
    indications_and_usage_exact
    source text sha256
    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
    start
    0
    current approval status
    not_reconciled
    duplicate text group
    dup-8a109b46ffe233c10372
    extraction review status
    automated_candidate_pending_source_review
    generic names
    1. LENALIDOMIDE
    id
    ind-span-7f618b6afbbc1b259b9f
    label id
    9329fd28-b848-4013-92e0-a68270328336
    positive predicate support span
    end
    68
    end exclusive
    true
    exact text
    is a thalidomide analogue indicated
    label id
    9329fd28-b848-4013-92e0-a68270328336
    offset unit
    unicode_code_points
    source array index
    0
    source field
    indications_and_usage_exact
    source text sha256
    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
    start
    33
    qualifier mentions
    1. context exact
      ID is a thalidomide analogue indicated for the treatment of adult patients with:
      kind
      age
      polarity
      not_inferred
      span
      end
      104
      end exclusive
      true
      exact text
      adult patients
      label id
      9329fd28-b848-4013-92e0-a68270328336
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
      start
      90
    regulatory links
      schema version
      0.1.0
      source batch sha256
      424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
      source defined aliases
      1. abbreviation
        FL
        definition exact
        follicular lymphoma
        definition span
        end
        668
        end exclusive
        true
        exact text
        follicular lymphoma (FL)
        label id
        9329fd28-b848-4013-92e0-a68270328336
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
        start
        644
      2. abbreviation
        MM
        definition exact
        Multiple myeloma
        definition span
        end
        134
        end exclusive
        true
        exact text
        Multiple myeloma (MM)
        label id
        9329fd28-b848-4013-92e0-a68270328336
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
        start
        113
      source span
      end
      110
      end exclusive
      true
      exact text
      1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with:
      label id
      9329fd28-b848-4013-92e0-a68270328336
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
      start
      0
      source url
      https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
      spl effective date
      2023-03-24
      spl set id
      5fa97bf5-28a2-48f1-8955-f56012d296be
      spl version
      41
      structured fields status
      not_extracted_no_values_inferred_from_mentions
      structured indication
      age
      Source null
      approval pathway
      Source null
      biomarker and test
      Source null
      disease stage
      Source null
      limitations
      Source null
      line
      Source null
      prior therapy
      Source null
      regimen
      Source null
      tumor histology
      Source null
      use intent
      non_oncology_or_unclear_candidate
      Passage 2 · positive indication candidate
      application numbers
      1. NDA021880
      brand names
      1. Revlimid
      classification reasons
      1. inherited_predicate_from_same_label_section_requires_review
      2. tumor_or_malignant_hematology_words_in_positive_statement
      clinical review status
      pending
      content role
      positive_indication_candidate
      context span
      end
      378
      end exclusive
      true
      exact text
      1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS
      label id
      9329fd28-b848-4013-92e0-a68270328336
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
      start
      0
      current approval status
      not_reconciled
      duplicate text group
      dup-f60ff78ccf5d1c1864d0
      extraction review status
      automated_candidate_pending_source_review
      generic names
      1. LENALIDOMIDE
      id
      ind-span-d03a200554dd3de36b54
      label id
      9329fd28-b848-4013-92e0-a68270328336
      positive predicate support span
      end
      68
      end exclusive
      true
      exact text
      is a thalidomide analogue indicated
      label id
      9329fd28-b848-4013-92e0-a68270328336
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
      start
      33
      qualifier mentions
      1. context exact
        • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ).
        kind
        regimen
        polarity
        not_inferred
        span
        end
        173
        end exclusive
        true
        exact text
        in combination with dexamethasone ( 1
        label id
        9329fd28-b848-4013-92e0-a68270328336
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
        start
        136
      regulatory links
        schema version
        0.1.0
        source batch sha256
        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
        source defined aliases
        1. abbreviation
          FL
          definition exact
          follicular lymphoma
          definition span
          end
          668
          end exclusive
          true
          exact text
          follicular lymphoma (FL)
          label id
          9329fd28-b848-4013-92e0-a68270328336
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
          start
          644
        2. abbreviation
          MM
          definition exact
          Multiple myeloma
          definition span
          end
          134
          end exclusive
          true
          exact text
          Multiple myeloma (MM)
          label id
          9329fd28-b848-4013-92e0-a68270328336
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
          start
          113
        source span
        end
        178
        end exclusive
        true
        exact text
        • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ).
        label id
        9329fd28-b848-4013-92e0-a68270328336
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
        start
        111
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
        spl effective date
        2023-03-24
        spl set id
        5fa97bf5-28a2-48f1-8955-f56012d296be
        spl version
        41
        structured fields status
        not_extracted_no_values_inferred_from_mentions
        structured indication
        age
        Source null
        approval pathway
        Source null
        biomarker and test
        Source null
        disease stage
        Source null
        limitations
        Source null
        line
        Source null
        prior therapy
        Source null
        regimen
        Source null
        tumor histology
        Source null
        use intent
        tumor_directed_candidate
        Passage 3 · unclassified context
        application numbers
        1. NDA021880
        brand names
        1. Revlimid
        classification reasons
        1. no_unambiguous_positive_indication_predicate
        clinical review status
        pending
        content role
        unclassified_context
        context span
        end
        481
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2
        label id
        9329fd28-b848-4013-92e0-a68270328336
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
        start
        0
        current approval status
        not_reconciled
        duplicate text group
        dup-361ffba77646cb0ac3e9
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. LENALIDOMIDE
        id
        ind-span-c31854185af38b613acc
        label id
        9329fd28-b848-4013-92e0-a68270328336
        positive predicate support span
        Source null
        qualifier mentions
          regulatory links
            schema version
            0.1.0
            source batch sha256
            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
            source defined aliases
            1. abbreviation
              FL
              definition exact
              follicular lymphoma
              definition span
              end
              668
              end exclusive
              true
              exact text
              follicular lymphoma (FL)
              label id
              9329fd28-b848-4013-92e0-a68270328336
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
              start
              644
            2. abbreviation
              MM
              definition exact
              Multiple myeloma
              definition span
              end
              134
              end exclusive
              true
              exact text
              Multiple myeloma (MM)
              label id
              9329fd28-b848-4013-92e0-a68270328336
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
              start
              113
            source span
            end
            281
            end exclusive
            true
            exact text
            • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ).
            label id
            9329fd28-b848-4013-92e0-a68270328336
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
            start
            179
            source url
            https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
            spl effective date
            2023-03-24
            spl set id
            5fa97bf5-28a2-48f1-8955-f56012d296be
            spl version
            41
            structured fields status
            not_extracted_no_values_inferred_from_mentions
            structured indication
            age
            Source null
            approval pathway
            Source null
            biomarker and test
            Source null
            disease stage
            Source null
            limitations
            Source null
            line
            Source null
            prior therapy
            Source null
            regimen
            Source null
            tumor histology
            Source null
            use intent
            unclear
            Passage 4 · unclassified context
            application numbers
            1. NDA021880
            brand names
            1. Revlimid
            classification reasons
            1. no_unambiguous_positive_indication_predicate
            clinical review status
            pending
            content role
            unclassified_context
            context span
            end
            683
            end exclusive
            true
            exact text
            ment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combinatio
            label id
            9329fd28-b848-4013-92e0-a68270328336
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
            start
            82
            current approval status
            not_reconciled
            duplicate text group
            dup-5dd1209a19a16a85613b
            extraction review status
            automated_candidate_pending_source_review
            generic names
            1. LENALIDOMIDE
            id
            ind-span-5279f229614ab780f0bc
            label id
            9329fd28-b848-4013-92e0-a68270328336
            positive predicate support span
            Source null
            qualifier mentions
            1. context exact
              c syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ).
              kind
              regimen
              polarity
              not_inferred
              span
              end
              478
              end exclusive
              true
              exact text
              with or without additional cytogenetic abnormalities ( 1
              label id
              9329fd28-b848-4013-92e0-a68270328336
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
              start
              422
            regulatory links
              schema version
              0.1.0
              source batch sha256
              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
              source defined aliases
              1. abbreviation
                FL
                definition exact
                follicular lymphoma
                definition span
                end
                668
                end exclusive
                true
                exact text
                follicular lymphoma (FL)
                label id
                9329fd28-b848-4013-92e0-a68270328336
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                start
                644
              2. abbreviation
                MM
                definition exact
                Multiple myeloma
                definition span
                end
                134
                end exclusive
                true
                exact text
                Multiple myeloma (MM)
                label id
                9329fd28-b848-4013-92e0-a68270328336
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                start
                113
              source span
              end
              483
              end exclusive
              true
              exact text
              • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ).
              label id
              9329fd28-b848-4013-92e0-a68270328336
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
              start
              282
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
              spl effective date
              2023-03-24
              spl set id
              5fa97bf5-28a2-48f1-8955-f56012d296be
              spl version
              41
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              unclear
              Passage 5 · unclassified context
              application numbers
              1. NDA021880
              brand names
              1. Revlimid
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              822
              end exclusive
              true
              exact text
              Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Lim
              label id
              9329fd28-b848-4013-92e0-a68270328336
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
              start
              284
              current approval status
              not_reconciled
              duplicate text group
              dup-626b7449f23a2601144d
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. LENALIDOMIDE
              id
              ind-span-a6ac0401553064d3f2b9
              label id
              9329fd28-b848-4013-92e0-a68270328336
              positive predicate support span
              Source null
              qualifier mentions
              1. context exact
                • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ).
                kind
                stage_or_setting
                polarity
                not_inferred
                span
                end
                574
                end exclusive
                true
                exact text
                relapsed or progressed after two prior ther
                label id
                9329fd28-b848-4013-92e0-a68270328336
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                start
                531
              regulatory links
                schema version
                0.1.0
                source batch sha256
                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                source defined aliases
                1. abbreviation
                  FL
                  definition exact
                  follicular lymphoma
                  definition span
                  end
                  668
                  end exclusive
                  true
                  exact text
                  follicular lymphoma (FL)
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                  start
                  644
                2. abbreviation
                  MM
                  definition exact
                  Multiple myeloma
                  definition span
                  end
                  134
                  end exclusive
                  true
                  exact text
                  Multiple myeloma (MM)
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                  start
                  113
                source span
                end
                622
                end exclusive
                true
                exact text
                • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ).
                label id
                9329fd28-b848-4013-92e0-a68270328336
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                start
                484
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                spl effective date
                2023-03-24
                spl set id
                5fa97bf5-28a2-48f1-8955-f56012d296be
                spl version
                41
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                unclear
                Passage 6 · positive indication candidate
                application numbers
                1. NDA021880
                brand names
                1. Revlimid
                classification reasons
                1. inherited_predicate_from_same_label_section_requires_review
                2. tumor_or_malignant_hematology_words_in_positive_statement
                clinical review status
                pending
                content role
                positive_indication_candidate
                context span
                end
                918
                end exclusive
                true
                exact text
                ith or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patient
                label id
                9329fd28-b848-4013-92e0-a68270328336
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                start
                423
                current approval status
                not_reconciled
                duplicate text group
                dup-eaaede01696319b69dd2
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. LENALIDOMIDE
                id
                ind-span-3c8c719b759f647176be
                label id
                9329fd28-b848-4013-92e0-a68270328336
                positive predicate support span
                end
                68
                end exclusive
                true
                exact text
                is a thalidomide analogue indicated
                label id
                9329fd28-b848-4013-92e0-a68270328336
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                start
                33
                qualifier mentions
                1. context exact
                  • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ).
                  kind
                  prior_therapy_or_line
                  polarity
                  not_inferred
                  span
                  end
                  713
                  end exclusive
                  true
                  exact text
                  Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                  start
                  625
                2. context exact
                  • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ).
                  kind
                  regimen
                  polarity
                  not_inferred
                  span
                  end
                  713
                  end exclusive
                  true
                  exact text
                  in combination with a rituximab product ( 1
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                  start
                  670
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                  source defined aliases
                  1. abbreviation
                    FL
                    definition exact
                    follicular lymphoma
                    definition span
                    end
                    668
                    end exclusive
                    true
                    exact text
                    follicular lymphoma (FL)
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                    start
                    644
                  2. abbreviation
                    MM
                    definition exact
                    Multiple myeloma
                    definition span
                    end
                    134
                    end exclusive
                    true
                    exact text
                    Multiple myeloma (MM)
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                    start
                    113
                  source span
                  end
                  718
                  end exclusive
                  true
                  exact text
                  • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ).
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                  start
                  623
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                  spl effective date
                  2023-03-24
                  spl set id
                  5fa97bf5-28a2-48f1-8955-f56012d296be
                  spl version
                  41
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  tumor_directed_candidate
                  Passage 7 · unclassified context
                  application numbers
                  1. NDA021880
                  brand names
                  1. Revlimid
                  classification reasons
                  1. no_unambiguous_positive_indication_predicate
                  clinical review status
                  pending
                  content role
                  unclassified_context
                  context span
                  end
                  1018
                  end exclusive
                  true
                  exact text
                  disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multipl
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                  start
                  519
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-213ac1a490cf73822b17
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. LENALIDOMIDE
                  id
                  ind-span-9c4300a9be0c81ef276d
                  label id
                  9329fd28-b848-4013-92e0-a68270328336
                  positive predicate support span
                  Source null
                  qualifier mentions
                  1. context exact
                    • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ).
                    kind
                    prior_therapy_or_line
                    polarity
                    not_inferred
                    span
                    end
                    813
                    end exclusive
                    true
                    exact text
                    Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                    start
                    721
                  2. context exact
                    • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ).
                    kind
                    regimen
                    polarity
                    not_inferred
                    span
                    end
                    813
                    end exclusive
                    true
                    exact text
                    in combination with a rituximab product ( 1
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                    start
                    770
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                    source defined aliases
                    1. abbreviation
                      FL
                      definition exact
                      follicular lymphoma
                      definition span
                      end
                      668
                      end exclusive
                      true
                      exact text
                      follicular lymphoma (FL)
                      label id
                      9329fd28-b848-4013-92e0-a68270328336
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                      start
                      644
                    2. abbreviation
                      MM
                      definition exact
                      Multiple myeloma
                      definition span
                      end
                      134
                      end exclusive
                      true
                      exact text
                      Multiple myeloma (MM)
                      label id
                      9329fd28-b848-4013-92e0-a68270328336
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                      start
                      113
                    source span
                    end
                    818
                    end exclusive
                    true
                    exact text
                    • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ).
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                    start
                    719
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                    spl effective date
                    2023-03-24
                    spl set id
                    5fa97bf5-28a2-48f1-8955-f56012d296be
                    spl version
                    41
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    unclear
                    Passage 8 · limitation of use
                    application numbers
                    1. NDA021880
                    brand names
                    1. Revlimid
                    classification reasons
                    1. limitation_heading
                    clinical review status
                    pending
                    content role
                    limitation_of_use
                    context span
                    end
                    1038
                    end exclusive
                    true
                    exact text
                    ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID i
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                    start
                    619
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-4caff49968a07e1a39f9
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. LENALIDOMIDE
                    id
                    ind-span-835eb2365604ae1848ed
                    label id
                    9329fd28-b848-4013-92e0-a68270328336
                    positive predicate support span
                    Source null
                    qualifier mentions
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                        source defined aliases
                        1. abbreviation
                          FL
                          definition exact
                          follicular lymphoma
                          definition span
                          end
                          668
                          end exclusive
                          true
                          exact text
                          follicular lymphoma (FL)
                          label id
                          9329fd28-b848-4013-92e0-a68270328336
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                          start
                          644
                        2. abbreviation
                          MM
                          definition exact
                          Multiple myeloma
                          definition span
                          end
                          134
                          end exclusive
                          true
                          exact text
                          Multiple myeloma (MM)
                          label id
                          9329fd28-b848-4013-92e0-a68270328336
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                          start
                          113
                        source span
                        end
                        838
                        end exclusive
                        true
                        exact text
                        Limitations of Use:
                        label id
                        9329fd28-b848-4013-92e0-a68270328336
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                        start
                        819
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                        spl effective date
                        2023-03-24
                        spl set id
                        5fa97bf5-28a2-48f1-8955-f56012d296be
                        spl version
                        41
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        not_applicable
                        Passage 9 · limitation of use
                        application numbers
                        1. NDA021880
                        brand names
                        1. Revlimid
                        classification reasons
                        1. negative_or_not_established_clause
                        clinical review status
                        pending
                        content role
                        limitation_of_use
                        context span
                        end
                        1206
                        end exclusive
                        true
                        exact text
                        ated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult pati
                        label id
                        9329fd28-b848-4013-92e0-a68270328336
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                        start
                        639
                        current approval status
                        not_reconciled
                        duplicate text group
                        dup-27b5164159ca2f03d63a
                        extraction review status
                        automated_candidate_pending_source_review
                        generic names
                        1. LENALIDOMIDE
                        id
                        ind-span-3ea05b7e37dae9a40183
                        label id
                        9329fd28-b848-4013-92e0-a68270328336
                        positive predicate support span
                        Source null
                        qualifier mentions
                          regulatory links
                            schema version
                            0.1.0
                            source batch sha256
                            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                            source defined aliases
                            1. abbreviation
                              FL
                              definition exact
                              follicular lymphoma
                              definition span
                              end
                              668
                              end exclusive
                              true
                              exact text
                              follicular lymphoma (FL)
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              644
                            2. abbreviation
                              MM
                              definition exact
                              Multiple myeloma
                              definition span
                              end
                              134
                              end exclusive
                              true
                              exact text
                              Multiple myeloma (MM)
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              113
                            source span
                            end
                            1006
                            end exclusive
                            true
                            exact text
                            • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ).
                            label id
                            9329fd28-b848-4013-92e0-a68270328336
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                            start
                            839
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                            spl effective date
                            2023-03-24
                            spl set id
                            5fa97bf5-28a2-48f1-8955-f56012d296be
                            spl version
                            41
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            not_applicable
                            Passage 10 · positive indication candidate
                            application numbers
                            1. NDA021880
                            brand names
                            1. Revlimid
                            classification reasons
                            1. explicit_positive_indication_predicate
                            2. tumor_or_malignant_hematology_words_in_positive_statement
                            clinical review status
                            pending
                            content role
                            positive_indication_candidate
                            context span
                            end
                            1347
                            end exclusive
                            true
                            exact text
                            ct ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated fo
                            label id
                            9329fd28-b848-4013-92e0-a68270328336
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                            start
                            807
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-4475001d42e4440bae04
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. LENALIDOMIDE
                            id
                            ind-span-791f9a67ab7c32a448cf
                            label id
                            9329fd28-b848-4013-92e0-a68270328336
                            positive predicate support span
                            end
                            1083
                            end exclusive
                            true
                            exact text
                            is indicated
                            label id
                            9329fd28-b848-4013-92e0-a68270328336
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                            start
                            1071
                            qualifier mentions
                            1. context exact
                              nation with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).
                              kind
                              age
                              polarity
                              not_inferred
                              span
                              end
                              1119
                              end exclusive
                              true
                              exact text
                              adult patients
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              1105
                            2. context exact
                              1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).
                              kind
                              regimen
                              polarity
                              not_inferred
                              span
                              end
                              1146
                              end exclusive
                              true
                              exact text
                              in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM)
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              1037
                            regulatory links
                              schema version
                              0.1.0
                              source batch sha256
                              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                              source defined aliases
                              1. abbreviation
                                FL
                                definition exact
                                follicular lymphoma
                                definition span
                                end
                                668
                                end exclusive
                                true
                                exact text
                                follicular lymphoma (FL)
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                start
                                644
                              2. abbreviation
                                MM
                                definition exact
                                Multiple myeloma
                                definition span
                                end
                                134
                                end exclusive
                                true
                                exact text
                                Multiple myeloma (MM)
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                start
                                113
                              source span
                              end
                              1147
                              end exclusive
                              true
                              exact text
                              1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              1007
                              source url
                              https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                              spl effective date
                              2023-03-24
                              spl set id
                              5fa97bf5-28a2-48f1-8955-f56012d296be
                              spl version
                              41
                              structured fields status
                              not_extracted_no_values_inferred_from_mentions
                              structured indication
                              age
                              Source null
                              approval pathway
                              Source null
                              biomarker and test
                              Source null
                              disease stage
                              Source null
                              limitations
                              Source null
                              line
                              Source null
                              prior therapy
                              Source null
                              regimen
                              Source null
                              tumor histology
                              Source null
                              use intent
                              tumor_directed_candidate
                              Passage 11 · positive indication candidate
                              application numbers
                              1. NDA021880
                              brand names
                              1. Revlimid
                              classification reasons
                              1. explicit_positive_indication_predicate
                              2. no_tumor_directed_keyword_in_positive_statement
                              3. source_defined_disease_abbreviation
                              clinical review status
                              pending
                              content role
                              positive_indication_candidate
                              context span
                              end
                              1492
                              end exclusive
                              true
                              exact text
                              kemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              948
                              current approval status
                              not_reconciled
                              duplicate text group
                              dup-6d30f48a99f18642ea78
                              extraction review status
                              automated_candidate_pending_source_review
                              generic names
                              1. LENALIDOMIDE
                              id
                              ind-span-ab6ee50a77c939db9430
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              positive predicate support span
                              end
                              1169
                              end exclusive
                              true
                              exact text
                              is indicated
                              label id
                              9329fd28-b848-4013-92e0-a68270328336
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                              start
                              1157
                              qualifier mentions
                              1. context exact
                                REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transp
                                kind
                                age
                                polarity
                                not_inferred
                                span
                                end
                                1210
                                end exclusive
                                true
                                exact text
                                adult patients
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                start
                                1196
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                source defined aliases
                                1. abbreviation
                                  FL
                                  definition exact
                                  follicular lymphoma
                                  definition span
                                  end
                                  668
                                  end exclusive
                                  true
                                  exact text
                                  follicular lymphoma (FL)
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  644
                                2. abbreviation
                                  MM
                                  definition exact
                                  Multiple myeloma
                                  definition span
                                  end
                                  134
                                  end exclusive
                                  true
                                  exact text
                                  Multiple myeloma (MM)
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  113
                                source span
                                end
                                1292
                                end exclusive
                                true
                                exact text
                                REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                start
                                1148
                                source url
                                https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                                spl effective date
                                2023-03-24
                                spl set id
                                5fa97bf5-28a2-48f1-8955-f56012d296be
                                spl version
                                41
                                structured fields status
                                not_extracted_no_values_inferred_from_mentions
                                structured indication
                                age
                                Source null
                                approval pathway
                                Source null
                                biomarker and test
                                Source null
                                disease stage
                                Source null
                                limitations
                                Source null
                                line
                                Source null
                                prior therapy
                                Source null
                                regimen
                                Source null
                                tumor histology
                                Source null
                                use intent
                                tumor_directed_candidate
                                Passage 12 · positive indication candidate
                                application numbers
                                1. NDA021880
                                brand names
                                1. Revlimid
                                classification reasons
                                1. explicit_positive_indication_predicate
                                2. supportive_or_complication_use_words
                                clinical review status
                                pending
                                content role
                                positive_indication_candidate
                                context span
                                end
                                1789
                                end exclusive
                                true
                                exact text
                                reatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which inc
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                start
                                1093
                                current approval status
                                not_reconciled
                                duplicate text group
                                dup-6e8c21ad0eb9d08272d1
                                extraction review status
                                automated_candidate_pending_source_review
                                generic names
                                1. LENALIDOMIDE
                                id
                                ind-span-ca467b186cba2d776800
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                positive predicate support span
                                end
                                1344
                                end exclusive
                                true
                                exact text
                                is indicated
                                label id
                                9329fd28-b848-4013-92e0-a68270328336
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                start
                                1332
                                qualifier mentions
                                1. context exact
                                  lastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermedia
                                  kind
                                  age
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  1380
                                  end exclusive
                                  true
                                  exact text
                                  adult patients
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  1366
                                2. context exact
                                  (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
                                  kind
                                  regimen
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  1588
                                  end exclusive
                                  true
                                  exact text
                                  with or without additional cytogenetic abnormalities
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  1536
                                regulatory links
                                  schema version
                                  0.1.0
                                  source batch sha256
                                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                  source defined aliases
                                  1. abbreviation
                                    FL
                                    definition exact
                                    follicular lymphoma
                                    definition span
                                    end
                                    668
                                    end exclusive
                                    true
                                    exact text
                                    follicular lymphoma (FL)
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    644
                                  2. abbreviation
                                    MM
                                    definition exact
                                    Multiple myeloma
                                    definition span
                                    end
                                    134
                                    end exclusive
                                    true
                                    exact text
                                    Multiple myeloma (MM)
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    113
                                  source span
                                  end
                                  1589
                                  end exclusive
                                  true
                                  exact text
                                  1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  1293
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                                  spl effective date
                                  2023-03-24
                                  spl set id
                                  5fa97bf5-28a2-48f1-8955-f56012d296be
                                  spl version
                                  41
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  supportive_care_candidate
                                  Passage 13 · positive indication candidate
                                  application numbers
                                  1. NDA021880
                                  brand names
                                  1. Revlimid
                                  classification reasons
                                  1. explicit_positive_indication_predicate
                                  2. tumor_or_malignant_hematology_words_in_positive_statement
                                  clinical review status
                                  pending
                                  content role
                                  positive_indication_candidate
                                  context span
                                  end
                                  2006
                                  end exclusive
                                  true
                                  exact text
                                  sfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  1390
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-2946427b04319f28a462
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. LENALIDOMIDE
                                  id
                                  ind-span-3d53035c881982249057
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  positive predicate support span
                                  end
                                  1636
                                  end exclusive
                                  true
                                  exact text
                                  is indicated
                                  label id
                                  9329fd28-b848-4013-92e0-a68270328336
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                  start
                                  1624
                                  qualifier mentions
                                  1. context exact
                                    le Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed
                                    kind
                                    age
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1672
                                    end exclusive
                                    true
                                    exact text
                                    adult patients
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    1658
                                  2. context exact
                                    patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
                                    kind
                                    stage_or_setting
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1766
                                    end exclusive
                                    true
                                    exact text
                                    relapsed or progressed after two prior ther
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    1723
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                    source defined aliases
                                    1. abbreviation
                                      FL
                                      definition exact
                                      follicular lymphoma
                                      definition span
                                      end
                                      668
                                      end exclusive
                                      true
                                      exact text
                                      follicular lymphoma (FL)
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      644
                                    2. abbreviation
                                      MM
                                      definition exact
                                      Multiple myeloma
                                      definition span
                                      end
                                      134
                                      end exclusive
                                      true
                                      exact text
                                      Multiple myeloma (MM)
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      113
                                    source span
                                    end
                                    1806
                                    end exclusive
                                    true
                                    exact text
                                    1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    1590
                                    source url
                                    https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                                    spl effective date
                                    2023-03-24
                                    spl set id
                                    5fa97bf5-28a2-48f1-8955-f56012d296be
                                    spl version
                                    41
                                    structured fields status
                                    not_extracted_no_values_inferred_from_mentions
                                    structured indication
                                    age
                                    Source null
                                    approval pathway
                                    Source null
                                    biomarker and test
                                    Source null
                                    disease stage
                                    Source null
                                    limitations
                                    Source null
                                    line
                                    Source null
                                    prior therapy
                                    Source null
                                    regimen
                                    Source null
                                    tumor histology
                                    Source null
                                    use intent
                                    tumor_directed_candidate
                                    Passage 14 · positive indication candidate
                                    application numbers
                                    1. NDA021880
                                    brand names
                                    1. Revlimid
                                    classification reasons
                                    1. explicit_positive_indication_predicate
                                    2. tumor_or_malignant_hematology_words_in_positive_statement
                                    clinical review status
                                    pending
                                    content role
                                    positive_indication_candidate
                                    context span
                                    end
                                    2179
                                    end exclusive
                                    true
                                    exact text
                                    ymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    1607
                                    current approval status
                                    not_reconciled
                                    duplicate text group
                                    dup-d2437021fc4a7faccd0d
                                    extraction review status
                                    automated_candidate_pending_source_review
                                    generic names
                                    1. LENALIDOMIDE
                                    id
                                    ind-span-72ebe6aa3029636ffb22
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    positive predicate support span
                                    end
                                    1893
                                    end exclusive
                                    true
                                    exact text
                                    is indicated
                                    label id
                                    9329fd28-b848-4013-92e0-a68270328336
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                    start
                                    1881
                                    qualifier mentions
                                    1. context exact
                                      with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
                                      kind
                                      age
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      1929
                                      end exclusive
                                      true
                                      exact text
                                      adult patients
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      1915
                                    2. context exact
                                      duct, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
                                      kind
                                      prior_therapy_or_line
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      1978
                                      end exclusive
                                      true
                                      exact text
                                      previously treated follicular lymphoma (FL)
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      1935
                                    3. context exact
                                      1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
                                      kind
                                      regimen
                                      polarity
                                      not_inferred
                                      span
                                      end
                                      1978
                                      end exclusive
                                      true
                                      exact text
                                      in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL)
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      1840
                                    regulatory links
                                      schema version
                                      0.1.0
                                      source batch sha256
                                      424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                      source defined aliases
                                      1. abbreviation
                                        FL
                                        definition exact
                                        follicular lymphoma
                                        definition span
                                        end
                                        668
                                        end exclusive
                                        true
                                        exact text
                                        follicular lymphoma (FL)
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        644
                                      2. abbreviation
                                        MM
                                        definition exact
                                        Multiple myeloma
                                        definition span
                                        end
                                        134
                                        end exclusive
                                        true
                                        exact text
                                        Multiple myeloma (MM)
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        113
                                      source span
                                      end
                                      1979
                                      end exclusive
                                      true
                                      exact text
                                      1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      1807
                                      source url
                                      https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                                      spl effective date
                                      2023-03-24
                                      spl set id
                                      5fa97bf5-28a2-48f1-8955-f56012d296be
                                      spl version
                                      41
                                      structured fields status
                                      not_extracted_no_values_inferred_from_mentions
                                      structured indication
                                      age
                                      Source null
                                      approval pathway
                                      Source null
                                      biomarker and test
                                      Source null
                                      disease stage
                                      Source null
                                      limitations
                                      Source null
                                      line
                                      Source null
                                      prior therapy
                                      Source null
                                      regimen
                                      Source null
                                      tumor histology
                                      Source null
                                      use intent
                                      tumor_directed_candidate
                                      Passage 15 · positive indication candidate
                                      application numbers
                                      1. NDA021880
                                      brand names
                                      1. Revlimid
                                      classification reasons
                                      1. explicit_positive_indication_predicate
                                      2. tumor_or_malignant_hematology_words_in_positive_statement
                                      clinical review status
                                      pending
                                      content role
                                      positive_indication_candidate
                                      context span
                                      end
                                      2348
                                      end exclusive
                                      true
                                      exact text
                                      which included bortezomib. 1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of Use REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) ] .
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      1780
                                      current approval status
                                      not_reconciled
                                      duplicate text group
                                      dup-7cf8a7029ae73b137e8d
                                      extraction review status
                                      automated_candidate_pending_source_review
                                      generic names
                                      1. LENALIDOMIDE
                                      id
                                      ind-span-bf8bfc591b9380129156
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      positive predicate support span
                                      end
                                      2069
                                      end exclusive
                                      true
                                      exact text
                                      is indicated
                                      label id
                                      9329fd28-b848-4013-92e0-a68270328336
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                      start
                                      2057
                                      qualifier mentions
                                      1. context exact
                                        with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
                                        kind
                                        age
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        2105
                                        end exclusive
                                        true
                                        exact text
                                        adult patients
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        2091
                                      2. context exact
                                        duct, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
                                        kind
                                        prior_therapy_or_line
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        2158
                                        end exclusive
                                        true
                                        exact text
                                        previously treated marginal zone lymphoma (MZL)
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        2111
                                      3. context exact
                                        1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
                                        kind
                                        regimen
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        2158
                                        end exclusive
                                        true
                                        exact text
                                        in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL)
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        2016
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                        source defined aliases
                                        1. abbreviation
                                          FL
                                          definition exact
                                          follicular lymphoma
                                          definition span
                                          end
                                          668
                                          end exclusive
                                          true
                                          exact text
                                          follicular lymphoma (FL)
                                          label id
                                          9329fd28-b848-4013-92e0-a68270328336
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                          start
                                          644
                                        2. abbreviation
                                          MM
                                          definition exact
                                          Multiple myeloma
                                          definition span
                                          end
                                          134
                                          end exclusive
                                          true
                                          exact text
                                          Multiple myeloma (MM)
                                          label id
                                          9329fd28-b848-4013-92e0-a68270328336
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                          start
                                          113
                                        source span
                                        end
                                        2159
                                        end exclusive
                                        true
                                        exact text
                                        1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        1980
                                        source url
                                        https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                                        spl effective date
                                        2023-03-24
                                        spl set id
                                        5fa97bf5-28a2-48f1-8955-f56012d296be
                                        spl version
                                        41
                                        structured fields status
                                        not_extracted_no_values_inferred_from_mentions
                                        structured indication
                                        age
                                        Source null
                                        approval pathway
                                        Source null
                                        biomarker and test
                                        Source null
                                        disease stage
                                        Source null
                                        limitations
                                        Source null
                                        line
                                        Source null
                                        prior therapy
                                        Source null
                                        regimen
                                        Source null
                                        tumor histology
                                        Source null
                                        use intent
                                        tumor_directed_candidate
                                        Passage 16 · limitation of use
                                        application numbers
                                        1. NDA021880
                                        brand names
                                        1. Revlimid
                                        classification reasons
                                        1. negative_or_not_established_clause
                                        clinical review status
                                        pending
                                        content role
                                        limitation_of_use
                                        context span
                                        end
                                        2348
                                        end exclusive
                                        true
                                        exact text
                                        ular lymphoma (FL). 1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of Use REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) ] .
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                        start
                                        1960
                                        current approval status
                                        not_reconciled
                                        duplicate text group
                                        dup-d1044db658d6174e882d
                                        extraction review status
                                        automated_candidate_pending_source_review
                                        generic names
                                        1. LENALIDOMIDE
                                        id
                                        ind-span-3ee602faa9ae3e66bc48
                                        label id
                                        9329fd28-b848-4013-92e0-a68270328336
                                        positive predicate support span
                                        Source null
                                        qualifier mentions
                                          regulatory links
                                            schema version
                                            0.1.0
                                            source batch sha256
                                            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                            source defined aliases
                                            1. abbreviation
                                              FL
                                              definition exact
                                              follicular lymphoma
                                              definition span
                                              end
                                              668
                                              end exclusive
                                              true
                                              exact text
                                              follicular lymphoma (FL)
                                              label id
                                              9329fd28-b848-4013-92e0-a68270328336
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                              start
                                              644
                                            2. abbreviation
                                              MM
                                              definition exact
                                              Multiple myeloma
                                              definition span
                                              end
                                              134
                                              end exclusive
                                              true
                                              exact text
                                              Multiple myeloma (MM)
                                              label id
                                              9329fd28-b848-4013-92e0-a68270328336
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                              start
                                              113
                                            source span
                                            end
                                            2348
                                            end exclusive
                                            true
                                            exact text
                                            1.6 Limitations of Use REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) ] .
                                            label id
                                            9329fd28-b848-4013-92e0-a68270328336
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            fe77ddc197d03404159bc93eda0ad6ac7166f6b7f8d6d8392d73c9662aedd7cb
                                            start
                                            2160
                                            source url
                                            https://api.fda.gov/drug/label.json?search=id%3A%229329fd28-b848-4013-92e0-a68270328336%22
                                            spl effective date
                                            2023-03-24
                                            spl set id
                                            5fa97bf5-28a2-48f1-8955-f56012d296be
                                            spl version
                                            41
                                            structured fields status
                                            not_extracted_no_values_inferred_from_mentions
                                            structured indication
                                            age
                                            Source null
                                            approval pathway
                                            Source null
                                            biomarker and test
                                            Source null
                                            disease stage
                                            Source null
                                            limitations
                                            Source null
                                            line
                                            Source null
                                            prior therapy
                                            Source null
                                            regimen
                                            Source null
                                            tumor histology
                                            Source null
                                            use intent
                                            not_applicable

                                            Preserved source evidence · Not medical advice